Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
•
Hospital Medicine
Can the tracheostomy be reversed after completion of chemoradiation for laryngeal cancers?
At what disease free interval is the safest to consider this?
Answer from: Radiation Oncologist at Academic Institution
Yes, if there has been a CR. Wait 3 months. PET. If negative, plug trach for 2 weeks. If all is well, pull trach.
Sign in or Register to read more
13468
Related Questions
How would you manage a presumed radiation induced sarcoma of the head and neck?
Would you recommend adjuvant neck radiation for metastatic chordoma to cervical lymph node, s/p neck dissection, with 1/10 positive nodes and no residual on post op imaging?
Would you consider 50 Gy in 20 fractions for a primary head and neck malignancy in an elderly patient with poor KPS?
How should you approach treating curable laryngeal cancer with chemo-RT in a patient who had a myocardial infarction during treatment and requires CABG, given the cardiotoxicity of cisplatin and 5FU/carboplatin?
How would you approach post-op radiation recommendations in patients who had neoadjuvant chemoimmunotherapy for HPV mediated OPSCC s/p TORS who have a complete pathologic response (pCR)?
What dose and regimen would you treat a stage I laryngeal cancer s/p R1 resection?
How do you approach postoperative radiation therapy in a patient with head and neck cancer who has high risk of recurrence in the setting of active epidermolysis bullosa?
Would you modify your treatment approach for treating an HPV-positive head and neck cancer in a patient with symptomatic Sjogren's?
Are there any special treatment considerations when treating a patient with laryngeal cancer with significant Reinke's edema of the vocal folds?
For a patient s/p TORS with indications for adjuvant radiation, how does your management change with persistently elevated ctHPVDNA?